Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Plasmablastic Lymphoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 170Rituximab 164Specimen Handling 116Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 86Doxorubicin 81Prednisone 78fludarabine 70venetoclax 69obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 44Etoposide 43CT-P10 42blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 34Gemcitabine 33zanubrutinib 31prednylidene 31pembrolizumab 30glofitamab 30deltacortene 30Calcium Dobesilate 30Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
varlilumab × Lymphoid × 90 days × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡